Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine (Q43830776)

27 November 2017

Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine (English)

1 reference

27 November 2017

Tadashi Kumamoto

1

1 reference

27 November 2017

Eric K Huang

2

1 reference

27 November 2017

Hyun Joon Paek

3

1 reference

27 November 2017

Akimichi Morita

4

1 reference

27 November 2017

Hiroyuki Matsue

5

1 reference

27 November 2017

Robert F Valentini

6

1 reference

27 November 2017

Akira Takashima

7

1 reference

27 November 2017

1 January 2002

1 reference

27 November 2017

1 reference

27 November 2017

20

1 reference

27 November 2017

1

1 reference

27 November 2017

64-69

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt0102-64

27 November 2017

0 references

cites work

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Immunobiology of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Dendritic cells in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

The dendritic cell and human cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

The role of chemokine receptors in primary, effector, and memory immune responses

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

DNA immunization induces protective immunity against B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Macrophage inflammatory protein 3alpha is involved in the constitutive trafficking of epidermal langerhans cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors.

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Human osteoblast response in vitro to platelet-derived growth factor and transforming growth factor-beta delivered from controlled-release polymer rods

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Controlled and modulated release of basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking

1 reference

https://api.crossref.org/works/10.1038%2FNBT0102-64

7 January 2021

Identifiers

DOI

10.1038/NBT0102-64

1 reference

27 November 2017

1 reference